AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03286413 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: microwave ablation
Description: Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
Study NCT03286413 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: microwave ablation
Description: Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
Study NCT03294161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immucillin DI4G
Description: Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Study NCT03294161 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meglumine antimoniate
Description: Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
Study NCT01203774 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine insulin
Description: 20-180 units per day
Study NCT04313283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Taking Action
Description: A peer-led intervention, Parents Taking Action is the psychoeducational and child behavior management intervention led by trained Parent Leaders.
Study NCT02517359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 single dose
Description: Safety and tolerability of single doses
Study NCT02517359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 matching placebo single dose
Description: Safety and tolerability of single doses
Study NCT02517359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RV6153 14 day repeat dose
Description: Safety and tolerability of repeat doses
Study NCT00987974 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin 7 days
Description: atorvastatin 80 mg/day for 7 days.
Study NCT00987974 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo 7 days
Description: placebo 7 days
Study NCT03753165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise
Description: High intensity interval exercise at 80% of the maximal heart rate derived from the maximal graded exercise. Each individual will undergo 12 sessions of HIIE over a period of six weeks
Study NCT00785369 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Reflectance confocal microscopy
Description: Reflectance confocal microscopy (VivaScope 1500)
Study NCT03776513 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: an MRI examination
Description: The MRI examination implies the realization of an emotional associative memory task
Study NCT03776513 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an MRI examination
Description: The MRI examination implies the realization of an emotional associative memory task
Study NCT00949351 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aliskiren 300mg/d
Description: Aliskiren 300mg/d v.s. placebo for 12wk
Study NCT02859857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
Study NCT02791724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Desiconnect
Description: Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
Study NCT02791724 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CAU
Description: Care as Usual
Study NCT02791724 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAU
Description: Care as Usual
Study NCT00092131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Montelukast
Description: Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
Study NCT00092131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Placebo tablet administered orally as a single witnessed dose before exercise challenge
Study NCT02512575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9567 Monohydrat
Description: AZD9567 oral suspension 0.5 to 10 mg/ml
Study NCT02512575 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral suspension/ Placebo capsule
Description: Matching placebo
Study NCT02512575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
Study NCT04060394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase I and Phase II: LAE001/prednisone + afuresertib
Description: In the Phase I portion of the study will identify the RPD2 of the combined therapy. In the Phase II will evaluate LAE001/prednisone + afuresertib at the RP2D (Cohort 1) and docetaxel/prednisone + afuresertib (Cohort 2).
Study NCT03664700 — intervention group
Intervention type: DEVICE
Intervention: LMA Protector
Description: The LMA Protector will be inserted when a supraglottic device is needed
Study NCT03757299 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HPV Test
Description: Vaginal specimens for HPV test will be collected by participants themselves using flocked swabs after explanations by co-investigators. Two transport mediums will be used for those self-collected vaginal samples: NaCl 0.9%.
Study NCT03737955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Receive IV
Study NCT03737955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FUDR
Description: Floxuridine(FUDR) 0.12 mg/kg/day，on Day 1-14 through the HAI pump.
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 180 mg/m2 IV over 90 minutes on Day 1, 15.
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 ivd over 2 hours on Day 1
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin
Description: Leucovorin 200mg/m2 ivd over 2 hours on Day 1
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5FU
Description: 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5FU
Description: 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 180mg/m2
Study NCT03500874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: Irinotecan 180mg/m2
Study NCT03960190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using Eureka Breast Pump with Expression Kit
Description: Each subject will undergo two expression sessions for single and double electric pumping in randomized order to reduce the variation.
Study NCT03325712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 705564
Description: Film-coated tablet
Study NCT03325712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Film-coated tablet
Study NCT03325712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection
Study NCT03325712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Solution for injection
Study NCT03360253 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938 in drops
Description: L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle
Study NCT03360253 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo consists of an identical formulation except that the L. reuteri is not present
Study NCT00017381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00017381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00017381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT00017381 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 ibritumomab tiuxetan
Description: Given IV
Study NCT00017381 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo PBSCT
Study NCT00308009 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TVT and Prolapse surgery
Description: 1. TVT at the time of Prolapse surgery~2. TVT 3 months after Prolapse Surgery
Study NCT01268488 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ninja 2 Investigational Blood Glucose Meter
Description: Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
Study NCT00942799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644282 (28-day dosing schedule)
Description: Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
Study NCT00942799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genz-644282 (21-day dosing schedule)
Description: The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
Study NCT01706393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics (six probiotic cultures)
Description: Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
Study NCT01706393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
Study NCT01481701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m² / 14days
Study NCT01481701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: oxaliplatin
Study NCT03013725 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02683317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: docosahexaenoic acid
Description: Docosahexaenoic acid is a dietary supplement derived from algae.
Study NCT02683317 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: sunflower oil
Description: Sunflower similar to the excipient used in experimental group
Study NCT00834483 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knotless suture for wound closure
Description: Angiotech Quill SRS
Study NCT00834483 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Layered traditional wound closure (monocryl)
Description: Layered traditional wound closure (monocryl)
Study NCT00301015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid diagnostic test for malaria
Description: We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
Study NCT00301015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rapid diagnostic test for malaria
Description: We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
Study NCT02042625 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasopharyngeal
Study NCT02849509 — intervention group
Intervention type: DRUG
Intervention: Pradaxa (dabigatran)
Description: Pradaxa (dabigatran etexilate)110mg or 150mg
Study NCT02849509 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonist
Description: Vitamin K antagonist or Pradaxa
Study NCT00629161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)
Description: 12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
Study NCT00629161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 12 months period of placebo plus 1 month period without placebo
Study NCT02725359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Group Placebo: will receive a placebo pill 1 hour before surgery
Study NCT02725359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group Placebo: will receive a placebo pill 1 hour before surgery
Study NCT02725359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tizanidine
Description: Group T: 6 mg tizanidine1 hour before surgery
Study NCT02725359 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
Study NCT02725359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
Study NCT02725359 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: USG guided SCPB with saline bilaterally 10 ml each side
Study NCT03612453 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ENDS (vaporizer/e-cig) and smoking cessation counseling
Description: Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study NCT03612453 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation counseling
Description: Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 6-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6 months, participants will be asked to come to a final clinical visit.
Study NCT01976156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PhosphoLean
Description: PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
Study NCT01976156 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consists of rice flour
Study NCT00995618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranilast
Description: Tranilast tablets, 300 mg, QD
Study NCT00995618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Febuxostat
Description: Febuxostat Tablets, 40 mg, QD
Study NCT00995618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination - Tranilast and Febuxostat
Description: Tranilast, 300 mg QD; Febuxostat, 40 mg QD
Study NCT03359187 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline with salt/Soda
Description: Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
Study NCT03359187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinacanthus nutans
Description: Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
Study NCT03359187 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boesenbergia rotunda
Description: Head and Neck cancer Patients have to rinse 4 times a day/everyday for 15 ml. each time during and after completed the radiation treatment
Study NCT04502888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: SL-172154
Description: The investigational product (IP), SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Study NCT01248078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keflex
Description: 2g of i.v. cefazolin singleshot administered before skin incision
Study NCT01248078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keflex
Description: 2g of i.v. cefazolin singleshot administered after umbilical cord clamping
Study NCT01248078 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 100cc administered before skin incision
Study NCT00027963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gabapentin
Study NCT00027963 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT03709485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rectal swab for microbial culture.
Description: Rectal swab and culture.
Study NCT00873678 — intervention group
Intervention type: BIOLOGICAL
Intervention: Whole blood sample
Description: Whole blood sample (10 ml)
Study NCT04581356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voxelotor
Description: daily voxelotor 1500mg oral medication
Study NCT02001207 — intervention group
Intervention type: OTHER
Intervention: Salivary cortisol test
Study NCT02522299 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557
Description: GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device. Since GSK2269557 will no longer be manufactured for use with the DISKUS device, it will be replaced with ELLIPTA Device. Subjects will receive GSK2269557 700 mcg once daily for 84 consecutive days via ELLIPTA.
Study NCT02522299 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose will be administered using a DISKUS and ELLIPTA dry powder inhaler device
Study NCT02522299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DISKUS
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
Study NCT02522299 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DISKUS
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
Study NCT02522299 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ELLIPTA
Description: It is multi-dose dry powder inhaler containing one foil strip of drug with 30 blisters